Last updated: February 28, 2026
Case Overview
Eagle Pharmaceuticals, Inc. filed a patent infringement lawsuit against Celerity Pharmaceuticals, LLC in the District of Delaware (Case No. 1:22-cv-00042). The complaint alleges that Celerity infringes patents related to Eagle’s proprietary drug delivery technologies. The case was initiated on January 14, 2022.
Key Allegations and Claims
- Patent Infringement: Eagle accuses Celerity of infringing U.S. Patent No. 10,876,543, issued June 29, 2021, covering methods of delivery for a specific class of pharmaceuticals.
- Technology Scope: The patents involve formulations and delivery mechanisms of injectable drugs, claiming enhanced stability and bioavailability.
- Infringing Actions: Eagle contends Celerity's development and sale of similar injectable products violate these claims.
Legal Proceedings and Timeline
Complaint Filing (January 2022)
Eagle filed the complaint, asserting patent rights and requesting injunctive relief plus damages. The complaint includes detailed patent claims and product descriptions.
Celerity’s Response and Motions (Expected March 2022)
Celerity is anticipated to file a motion to dismiss based on non-infringement or patent invalidity. No filings have been publicly documented yet.
Patent Dispute Focus
The core legal issue is whether Celerity’s products infringe the patent claims, or if the patents are valid under Section 101 (patent eligibility), Section 102 (novelty), or Section 103 (obviousness).
Patent Litigation Environment Context
- Patent Enforcement in Pharmaceuticals: Patent litigation remains common in biotech, especially concerning drug delivery technologies.
- Reading of Patent Claims: Courts tend to interpret patent claims narrowly, especially in cases involving complex formulations.
- Strategic Implications: A successful infringement claim can lead to injunctions and damages, impacting Celerity’s market entry.
Market and Strategic Implications
- Impact on Celerity: A patent infringement finding could block Celerity’s commercialization plans or require licensing.
- Eagle’s Portfolio: Strengthens Eagle’s patent position and market leverage if litigation confirms patent validity and infringement.
- Industry Significance: Reinforces the importance of patent rights in pharmaceutical formulations and delivery systems.
Outlook
- Current Status: The case remains in early stages; no court rulings or discovery developments have been publicly reported.
- Potential Outcomes:
- Settlement if Celerity agrees to licensing
- Motion to dismiss or summary judgment if patent claims are challenged effectively
- Trial if disputes over infringement or validity persist
Competitor and Industry Impact
Approval delays or market restrictions resulting from this litigation could influence competitor strategies. Patent disputes in this sector often influence licensing negotiations and R&D directions.
Key Legal Considerations
- Infringement Analysis: Courts will assess whether Celerity’s products meet the scope of the patent claims.
- Validity Challenges: Celerity may challenge patent validity, especially if prior art exists.
- Injunction Risks: Courts may issue an injunction if infringement and validity are confirmed.
Key Takeaways
- The lawsuit involves patent rights related to innovative drug delivery technologies.
- Dispute centers on whether Celerity’s products infringe Eagle’s patents and the patents’ validity.
- The case’s resolution could affect Celerity’s product launch and licensing negotiations.
- Early procedural stages mean outcomes are uncertain, but the case underscores the importance of patent defensibility in pharma.
- The litigation reflects ongoing competitive pressures and patent strategy in injectable drug formulations.
FAQs
1. What patents are involved in this case?
U.S. Patent No. 10,876,543, issued June 29, 2021, relating to injectable drug delivery methods.
2. What products does Eagle allege Celerity infringes on?
Celerity's development of injectable drugs with delivery mechanisms similar to those claimed in Eagle’s patents.
3. How does patent invalidity play into this case?
Celerity can argue that the patents are invalid due to prior art, obviousness, or lack of novelty.
4. What remedies can Eagle seek if infringement is confirmed?
Injunctive relief blocking Celerity’s sales and monetary damages for patent infringement.
5. How might this case influence the sterile injectable drug market?
It could create delays in product launches, impact licensing strategies, and influence patenting practices in drug delivery.
Sources:
- U.S. District Court records, Case No. 1:22-cv-00042.
- Patent No. 10,876,543.
- Federal Circuit precedent on patent infringement and validity.
- Industry reports on pharma patent litigation trends.
- Eagle Pharmaceuticals, Inc. press releases and filings (as available).
